PHARMACOLOGICAL CHARACTERISTICS OF CATALEPSY INDUCED BY INTRACEREBROVENTRICULAR ADMINISTRATION OF HISTAMINE IN MICE - THE IMPORTANCE OF MUSCARINIC STEP IN CENTRAL CHOLINERGIC NEURONS

被引:11
作者
ONODERA, K
SHINODA, H
机构
[1] Department of Pharmacology, Tohoku University School of Dentistry, Sendai, 980, Seiryo-machi 4-1, Aoba-ku
来源
AGENTS AND ACTIONS | 1991年 / 33卷 / 1-2期
关键词
D O I
10.1007/BF01993150
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Histamine-induced catalepsy was antagonized potently by scopolamine, an antimuscarinic drug, and partially blocked by sparteine. Neither methylatropine nor antinicotinic drugs could reverse histamine-induced catalepsy. These results indicate the greater importance of muscarinic receptors rather than their nicotinic counterparts in histamine-induced catalepsy. Various antiparkinson drugs, i.e. biperiden and trihexyphenidyl, which have antimuscarinic activity or dopamine agonists, i.e. L-dopa, amantadine and bromocriptine, could antagonize the histamine-induced catalepsy to various degrees. Thus, catalepsy induced by icv histamine can be evoked not only by an activation of the histamine receptor, but also indirectly due to cholinergic and dopaminergic imbalance.
引用
收藏
页码:143 / 146
页数:4
相关论文
共 10 条
[1]   MECHANISM OF POTENTIATING EFFECT OF ANTIDEPRESSANT DRUGS ON PROTECTIVE INFLUENCE OF DIPHENHYDRAMINE IN EXPERIMENTAL CATATONIA - ROLE OF HISTAMINE [J].
CHOPRA, YM ;
DANDIYA, PC .
PHARMACOLOGY, 1974, 12 (06) :347-353
[2]  
GIAR DC, 1950, ARCH INTERN MED, V85, P284
[3]  
MULEY MP, 1981, J PHARM PHARMACOL, V34, P34
[4]  
NARABAYASHI H, 1987, JPN PHARMACOL THER, V15, P411
[5]   DOES HISTAMINE INTERACT WITH CHOLINERGIC NEURONS IN ITS CATALEPTOGENIC ACTION IN RAT [J].
NOWAK, JZ ;
PILC, A ;
LEBRECHT, U ;
MASLINSKI, C .
NEUROPHARMACOLOGY, 1977, 16 (12) :841-847
[6]  
ONODERA K, 1983, Japanese Journal of Pharmacology, V33, p14P
[7]  
ONODERA K, 1983, JPN J ORAL BIOL, V25, P1144
[8]  
SCHMIDT MJ, 1981, NEUROPHARMACOLOGY CE, P149
[9]  
YAGI A, 1990, ANN REP PHARMACOPSYC, V21, P295
[10]  
ZETLER G, 1971, NEUROPHARMACOLOGY, V110, P289